GSA Capital Partners’s Soleno Therapeutics SLNO Stock Holding History

GSA Capital Partners’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,465	Closed	-$216K	–	2138
2026 Q1	$216K	Buy	+6,465	New	+$253K	0.01%	1421

GSA Capital Partners's SLNO Position: Q2 2026 in Review

GSA Capital Partners sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 6,465 shares — an estimated $216K sold.

GSA Capital Partners first reported a position in SLNO in Q1 2026 and held it in 1 quarter. The position peaked at $216K in Q1 2026. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

GSA Capital Partners reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
GSA Capital Partners sold 6,465 Soleno Therapeutics shares in Q2 2026, an estimated $216K.
GSA Capital Partners first reported a position in Soleno Therapeutics in Q1 2026 and held it in 1 quarter.
GSA Capital Partners's Soleno Therapeutics position peaked at $216K in Q1 2026.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.